COMP <GO>
COAG vs ALVO // EV/EBITDA & P/E VALUATION
Hemab Therapeutics Holdings Inc. (NASDAQ) VS. Alvotech (NASDAQ) • 15-METRIC TALLY: COAG 1
— ALVO 1
■ METRIC PARITY
LAST: $40.42 (+4.99%) • MKT CAP: $1.89B
valuation
—
LAST: $4.89 (-1.01%) • MKT CAP: $1.91B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COAG VS. ALVO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COAG | ALVO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.2 | 38.9 | +28.31 | COAG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.89B | $1.91B | -$21.1M | ALVO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COAG REV | ALVO REV | COAG GROSS % | ALVO GROSS % | COAG FCF | ALVO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | — | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COAG // BETA —
ALVO // BETA —